




ONCOVITA

Unleashing patient's own power to destroy cancer

Triple Negative Breast Cancer (TNBC) cured by Measle Vaccine virus

- in TNBC < 50% survival rate at 5-years
- 40% of TNBC patients are refractory or relapse to the best currently available therapies

A Croatian virologist cured her breast cancer by self-administering an experimental treatment

By Elisa Doré, *Le Figaro Santé*

December 16, 2024



Beata Halassy chose to use two viral strains, including the classic measles vaccine to treat her breast cancer.



- ➡ Tumor size reduction
- ➡ IT injections well tolerated.
- ➡ Remission for 4 years.
- ➡ Neoadjuvant setting

Case report published in *Vaccines* in August 2024



Case Report

An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer

▲ Dubravko Forčić^{1,2,†}, Karmen Mršić^{3,†}, Melita Perić-Balja⁴, Tihana Kurtović^{1,2,‡}, Snježana Ramić⁴, Tajana Silovski⁵, Ivo Pedišić⁶, Ivan Milas⁷ and Beata Halassy^{1,2,*}





Figure 1. Oncolytic virotherapy (OVT) protocol and outcomes. (A) OVT time-course showing time-points of each individual virus administration (blue arrows for MeV and green ones for VSV) in relation to outcomes monitored as changes in tumour size (red symbols) and virus-specific neutralizing antibody titers (NT) (blue and green circles for anti-MeV and anti-VSV NT, respectively). (B) Details on viruses used for each application; CCID₅₀-cell culture infective dose 50.



Measovir® platform

- Designed by Dr Tangy, cofounder of Oncovita
- Based on the safe and efficient live attenuated measles virus vaccine (MV)

2024-2028 LabCom with Institut Pasteur

Licensed to




Acquired by



VACCINES

against infectious diseases

12 candidates; 4 in clinical trials:
Chikungunya, Zika, Lassa, Covid-19




In situ IMMUNOTHERAPY

against cancer

A candidate: **MVdeltaC**
Several 2nd generation products

From Measles vaccine to MVdeltaC

Measles live attenuated vaccine is one of the safest and most efficient human vaccines





- **Safety** : track record over **4 billion children vaccinated**
- **Efficacy** : Lifelong protective immunity
- **Specificity** : MV binds to CD 46 receptors overexpressed on tumor cells
-  **Deletion of virulence factor C** provides the virus with higher capacity to induce **immunogenic death of cancer cells**.
- **The C protein** is an inhibitor of IFN-I and a controller of apoptosis in unmodified MV.
- MVdeltaC produces massive amounts of DI-RNA agonists of RLRs and strongly activates IFN-I.

Pleural Mesothelioma (PM) :one of the Deadliest Solid Tumors


- Incidence ca 0,5/100 000 : rare disease
- Survival rate at 5-years: 5-10%
- Median survival rate 4-12 months
- Disease progression occurs in 80% of cases after standard 1st line treatment (nivo+ipi)




- **Measles vaccine virus** targets specifically **CD46** overexpressed on cancer cells



- Measles vaccine has a **natural tropism for cancer cells** (fluorescent virus).




- **MVdeltaC vs Standard treatment** in xenografted mice




ONCOLYTIC EFFECT > IMMUNOGENIC CELL DEATH > IMMUNE EFFECT

1 Strong *in vitro* oncolytic activity in tumor cell lines



- Oncolytic activity of MVdeltaC was evaluated *in vitro* on 127 human cell lines representing 8 different type of cancer.
- Enhanced and faster oncolytic activity compared to the standard vaccine virus (MV)
- Over 70% of cancers tested responded to treatment. No effect on healthy non cancer cells.


2 Antitumor *in vivo* activity in PDX models immunodeficient mice by intratumoral administration



- Inhibition of tumor growth (low dose)
- Complete tumor lysis (high dose)


ONCOLYTIC EFFECT > IMMUNOGENIC CELL DEATH > IMMUNE EFFECT

3 Antitumor activity in immunocompetent syngeneic A/J mice grafted mouse NS20Y neuroblastoma by IT administration



- Tumor growth was inhibited after only 3 IT injections, with a complete response in 72% of MVdeltaC-treated animals and high survival rate.
- A rechallenge performed 64 days later showed no tumor growth demonstrating the establishment of a long-lasting immune memory.

4 Massive infiltration of CD4+ and CD8+ T lymphocytes in MVdeltaC treated tumors



- Recruitment of CD8+ and natural killer lymphocytes demonstrate the role of innate and adaptive immune system in MVdeltaC tumor rejection.



Advantages of Measles platform as compared to other platforms



Platforms Companies	Measles Oncovita Vyriad	Herpes Simplex CG Oncology Amgen* Dailchi Sankyo * Replimune	Vaccinia (Pox) Imugène Kalivir Transgene	Vesicular Stomatitis Boehringer Ingelheim Vyriad Oncolytic Bioetch	Adeno Ferring* Tilt Candel Therapeutics
Specificity for cancer cells	+++ CD 46	+	+	+	-
Safety data on humans	+++ Measles vaccine : 4 billion vaccinated individuals	++ Registered product	++ Animal origin, cow pox	- Animal origin, rhabdo virus, neurotrope	++ Registered product
Efficacy data Clinical trials	+++ Mayo Clinic trial , Beata Halassy case report	+++ Registered product	-	+ Phase I trial	+++ Registered product
Induced immune memory	+++	++	++	++	+
Genome Stability Genetic material	+++ Neg. ss RNA	+++ ds DNA	+++ ds DNA	+++ Neg. ss RNA	+++ ds DNA
Efficacious dose in IT injection (PFU)	+++ 10^6 - 10^7	++ 10^6 - 10^8	+ 10^7 - 10^9	- 10^8 - 10^{11}	- 10^{10} - 10^{12}

* Approved product

ss : single stranded ds : double stranded



Market Opportunity

- ~9000 eligible patients per year in EU, US and in Japan
- Estimated **peak sales / €600M** on initial indications
- ODD for MVdeltaC in PM granted by FDA on going in the EU

Future Growth Drivers

- Can address all **solid tumor market** ie **€500 billion**
- Potential for combination with ICIs

This stepwise strategy builds early proof in an orphan indication and then extends MVdeltaC into larger solid tumor markets where revealing hidden tumors is a transformative advantage.

Oncovita receives ODD for **MVdeltaC** for the treatment of **Pleural Mesothelioma**




2 hearings with french regulatory agency on preclinical and manufacturing



Mesothelioma is the first indication, supported by orphan designation, strong data, and a clear accelerated development path.

TNBC based on documented human benefit, complete preclinical regressions, and mechanistic fit for tumor revealing virotherapy.

Development plan and milestones



2024

2025

2026



Process development

Oxford Biomedica (FR)

Upstream & Downstream
process technologies
screening
Formulation development &
preliminary stability
Analytical development

Scale-up

Bespak*bio (AT)

USP & DSP optimization
upscaling from 2L to 50L


Cell Stacks GMP Manufacturing

Master Virus Seed

Engineering run

Clinical batch

Fix bed technology better appropriate
for larger trials and commercialization



Team and Advisory Board

Management Team



Jean-François Le Bigot, PhD
Executive Chairman



Stéphane Altaba, PhD, ESCP
CEO



Frédéric Tangy, PhD
CSO & Founder



Stéphane Champiat, MD, PhD
Medical Advisor



Patrick Spies
CFO



Véronique Riebbels, PhD,
Program Manager



Sarah Findakly
Head of CMC



KOLs involved



Pr. Aurelien Marabelle MD, PhD
Professor of Clinical Immunology
Paris-Saclay University
Clinical Director at Gustave
Roussy



Pr. Eric Deutsch, MD, PhD
Chairman of Radiation
Oncology at Gustave Roussy




Barbara Pistilli, MD
Head of the Breast
Cancer Unit at
Gustave Roussy



Jean Francois Fonteneau, PhD
Cancer Immunotherapy &
Oncolytic Virotherapy, Nantes
University



Pr. Arnaud Scherpereel, MD, PhD
Pulmonary and Thoracic Oncology
Department. Lille University
Hospital


Milestones	Status & Key Achievements	Next Steps
Mechanism of Action	 ✓ Validated (publications available)	Full MoA publication under review
Non-Clinical Validation	 ✓ Completed -in vitro -in vivo (immunodeficient & immunocompetent mice model) - TNBC & PM, - combination with a check point inhibitor - abscopal effect	PoC in other indications
Regulatory Interactions (GIO/ANSM)	 ✓ Meeting held on preclinical results ✓ Meeting held on manufacturing	meeting on Phase 1 synopsis (briefing book Q4 2026)
Manufacturing	 ✓ Process development & analytical methods validated ✓ GMP process finalized	CMDO selection by Q3 2026 GMP batch production Q1 2027
Clinical Trial (FHI) preparation	 🔄 Data review & synopsis fine tuning	Finalisation by Q2 2026
Market Access	 ✓ ODD granted in the US and in EU	
Partnerships	 ✓ collaboration with InfinitusbioAI using human digital cell clones to accelerate development of new candidates	Develop new partnerships with Pharma

Strategic partnership between Infinitusbio.AI and Oncovita



Oncovita announces a San Diego, USA, and Paris, France – January 12, 2026. infinitusbio.AI, a U.S.-based Pharmatech company and creator of the proprietary Simulative AI Digital Cell Clone platform, and Oncovita, announce a strategic partnership aimed at accelerating the development of next-generation cancer immunotherapies while creating long-term value for both companies..

Key Highlights of the Partnership:



ONCOVITA



Contact Information :

Stéphane Altaba, PhD, ESCP
CEO

28 rue du Docteur Roux
75724 Paris Cedex 15
Phone: +33 (0)6 72 87 20 03
Email: stephane.altaba@oncovita.fr

Patrick Spies
CFO

28 rue du Docteur Roux
75724 Paris Cedex 15
Phone: +33 (0)6 19 39 31 91
Email: patrick.spies@oncovita.fr

